(Q45935774)

English

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.

scientific article published in September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

object named as

Nezam H Afdhal

2

0 references

author name string

Yves Benhamou

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

David R Nelson

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

Mitchell L Shiffman

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

Deanine G Halliman

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

Jamie Heise

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

Eric Chun

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

Paul J Pockros

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

language of work or name

0 references

publication date

1 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

50

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

717-726

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Definition and management of anemia in patients infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Management of the hematologic complications of hepatitis C therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

The effects of HCV infection and management on health-related quality of life

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Hematologic side effects of interferon and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Anemia and clinical outcomes in hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23073

21 January 2018

Identifiers

10.1002/HEP.23073

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19585653

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45935774&oldid=1540635289"